Immuron Limited Sponsored ADR
(NASDAQ : IMRN)

( )
IMRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.11%358.111.2%$821.20m
AMGNAmgen Inc.
-0.54%191.761.2%$548.88m
CELGCelgene Corporation
-0.51%85.341.2%$519.45m
GILDGilead Sciences, Inc.
-0.09%77.050.9%$473.46m
VRTXVertex Pharmaceuticals Incorporated
-0.56%180.121.9%$315.55m
REGNRegeneron Pharmaceuticals, Inc.
0.48%367.742.6%$284.44m
ILMNIllumina, Inc.
0.59%309.103.5%$264.44m
SRPTSarepta Therapeutics, Inc.
0.14%135.5316.6%$232.12m
BLUEBluebird Bio, Inc.
-0.33%178.9515.7%$201.94m
ALXNAlexion Pharmaceuticals, Inc.
-0.41%135.092.0%$176.54m
NKTRNektar Therapeutics
2.51%49.085.6%$174.06m
EXASExact Sciences Corporation
1.30%67.6125.4%$158.76m
EXELExelixis, Inc.
0.05%21.346.4%$136.40m
BMRNBioMarin Pharmaceutical Inc.
0.18%102.874.4%$125.14m
AAgilent Technologies, Inc.
1.84%64.151.5%$122.61m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers corporate activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.